Category Archives: Investment

Why Pacific Biosciences’ crash landing epitomizes the classic overreaction; now what

The News: Pacific Biosciences of California Inc. (Nasdaq:PACB) skidded $1.11, or 22% last week, to $3.94 in response to a wider-than-expected first-quarter loss. Wall Street was expecting the Menlo Park,… Read more »

Akebia shares soar on rich partnership with Otsuka; risky but rational gamble?

The News: Akebia Therapeutics Inc. (Nasdaq:AKBA) led advancing issues last week, soaring $4.08, or 45% for the 5-day stretch, to $13.18. The big move came after the Cambridge, MA-based company… Read more »

Anthem defies Wall Street, rivals, with stellar 1Q results pegged to Obamacare business

The News: Anthem Inc. (Indianapolis IN), which has 1.1 million customers in individual Obamacare plans, said it was moving ahead with its 2018 insurance filings but had told state regulators… Read more »

Novartis 1Q results remain insomnia cure; investors plead for something, anything to get excited about

The News: Novartis AG shares moved higher Tuesday (April 25, 2017) after the pharmaceuticals group clung to full-year earnings targets and barely beat analysts’ estimates for first-quarter earnings. The Swiss… Read more »

Week’s opening stock salvo: Cleveland BioLabs, ImmunoGen lead winners; XBiotech, OncoMed crash

Among the top winners and losers in the healthcare sector last week, the following four were standouts and bear watching or acting upon, depending, as always, on one’s risk tolerance…. Read more »

Healthcare stocks have rough week as TherapeuticsMD, NantHealth fall flat; but Neurocrine, Tocagen shine

TherapeuticsMD Inc.(NYSE: TXMD) led a large contingent of stocks performing faceplants among the healthcare ranks. The clinical-stage biotech company focused on women’s health, plummeted $2.19, or 28%, to $7.70 in… Read more »

Week’s opening stock roundup: gainers include Novocure, Steadymed; but Corvus, NewLink rocked

Here to start your trading week are the major movers from last week and where they stand this morning: Novocure (Nasdaq: NVCR) led advancing issues, soaring $3.25, or 40% over the… Read more »

Canadian biopharma Zymeworks files for $75 million IPO; name may sound funky but gameplan dead serious

Biopharmaceutical company Zymeworks Inc. (Vancouver BC) on Monday (April 3, 2107) said it has filed with the US Securities and Exchange Commission for an initial public offering. The company, which… Read more »

Week’s opening stock roundup: Impax, Omeros shine; Foamix down, but not out

1) Impax Laboratories Inc. (Nasdaq:IPXL) led advancing issues, rocketing $3.40, or 37% over the week, to $12.65. The upward move came after the company reported it has hired Allergan PLC’s… Read more »

Week’s opening stock salvo: Cellect, Impax, Cancer Genetics celebrate; Foamix, not so much

After the resounding thud heard round-the-world Friday upon the failure of Trumpcare, healthcare stocks were back in vogue with investors Monday (March 27, 2017). Here are the top stars and… Read more »